Skip to content

A Clinical Study to Evaluate the Effect of Vruddhadaru Ghanavati in the Management of Chittodvega. (Generalized Anxiety Disorder)

A RANDOMIZED CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY OF VRUDDHADARU GHANAVATI IN THE MANAGEMENT OF CHITTODVEGA (GENERALIZED ANXIETY DISORDER).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/12/099749
Enrollment
120
Registered
2025-12-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F40-F48- Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders

Interventions

None listed

Sponsors

Dr Abhijit Baburao Shinde
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Excessive anxiety and worry occurring more days than not for at least 6 months, about a no. of events or activities The individual finds it difficult to control the worry. The anxiety and worry are associated with three (or more) of the following six symptoms (with at least some symptoms having been present for more days than not for the past 6 months): Restlessness or feeling keyed up or on edge. Being easily Fatigued Difficulty concentrating or mind going blank. Irritability Muscle tension Sleep disturbance (difficulty in falling or staying sleep or restless, unsatisfying) The anxiety worry or physical symptoms cause clinically significant distress or impairment in social, occupational or other important areas of functioning. The disturbance is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication) or another medical condition (e.g., hyperthyroidism). Patients who are willing to participate and provide informed consen

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women. 2. Patients with major psychiatric disorders other than GAD like schizophrenia, bipolar disorder etc. 3. History of allergic reactions to herbal products. 4. Patients having any major systemic disorders such as cardiac, renal, hepatic, or neurological diseases excluded. 5. Patients currently taking other anti-anxiety medications or undergoing psychotherapy.

Design outcomes

Primary

MeasureTime frame
1. Reduction in classical symptoms of Chittodvega. 2. Mean reduction in anxiety levels.Timepoint: 1st day of intervention 4th week 8th week

Secondary

MeasureTime frame
Improvement in sleep quality & overall quality of lifeTimepoint: 1st day of intervention 4th week 8th week

Countries

India

Contacts

Public ContactDr Abhijit Baburao Shinde

Bharati Vidyapeeth (Deemed To Be University)College of Ayurved And Hospital Pune

virendra.pawar@bharatividyapeeth.edu9096743333

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026